# Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

> **NCT01754376** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 6 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Aldesleukin
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01754376
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-02
- **Final completion:** 2016-03
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** changes in available treatments for melanoma
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01754376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01754376, "Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01754376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*